Shares of iRadimed fell 5.6% to $91.70 in one session.
On the numbers front it is hard to nitpick: revenue reached $83.8M in 2025, up 14.4% year over year, gross margin sits at 76.7%, operating margin at 31.2% and net margin at 26.8%.
"We also expect higher operating expenses compared to the fiscal year 2025 primarily due to higher sales and marketing, regulatory, and general and administrative expenses." (iRadimed / 10-Q / 2026-05-01)
Management is explicit about the offset: they plan to spend more on sales and marketing, regulatory work and corporate overhead. That is a clear, filing-level reason why an otherwise clean P&L might feel less bulletproof than the headline margins suggest.
"For the three and six months ended June 30, 2025, our effective tax rate was consistent at 21.2%, and differed from the U.S. federal statutory rate primarily due to U.S. state income tax expense, partially offset by benefits from research and development tax credits." (iRadimed / 10-Q / 2026-07-31)
On the flip side, the company is capturing tax benefits from R&D credits, which the filing says partially offset state income tax, a tailwind to after-tax profitability.
Filings also carry a second, less mathematical headwind: repeated legal and regulatory exposure flagged across three reports. That is not a quote; it is a plain fact from the filings. Put together, higher planned operating spend and recurring regulatory mentions are the concrete, company-stated frictions the market can price.
Meanwhile the company trades at a P/E of 52.4x. The company’s own scenario work shows a wide gap between bull and bear outcomes that comes mostly from what multiple investors apply at the end of the period. The firm’s scenario drivers list a bull revenue CAGR of 21.5%, a base of 16.3% and a bear of 6.5%, with the bull and base exit multiple at 52.4x and the bear exit multiple at 36.7x. The spread between those exit assumptions is the dominant variable in outcomes.
That arithmetic explains the tension: on one hand, robust single-digit-to-teen growth and high margins; on the other, higher planned spending, recurring regulatory/legal notes, and a valuation that incorporates the higher-growth assumptions from the scenarios. The one-day drop followed the filings.
Quick context: market cap is $1.2B and enterprise value $1.1B; the stock is up 59.3% over 12 months but down 7.3% over six months. Diluted shares rose 0.5% in the last year.
The filings highlight that a high-margin, modestly fast-growing med-dev company can be sensitive to higher recurring spending and regulatory noise. That is the practical tension priced into the shares today.
Source: iRadimed filings (10-Q 2026-07-31; 10-Q 2026-05-01).